Purpose: To study the safety and efficacy of 1/3-dose verteporfin photodynamic therapy (PDT) for subacute central serous chorioretinopathy (CSC). Methods: In this case series, 59 eyes (59 patients) diagnosed with suba...Purpose: To study the safety and efficacy of 1/3-dose verteporfin photodynamic therapy (PDT) for subacute central serous chorioretinopathy (CSC). Methods: In this case series, 59 eyes (59 patients) diagnosed with subacute CSC in Shenyang the 4th hospital from January 2014 to December 2015 were treated with 1/3-dose verteporfin PDT and followed up for at least 1 year. The symptoms and the diagnosed history were more than 3 months but shorter than 6 months. The central foveal thickness (CFT), neuroretinal thickness (NRT), height of subfoveal retinal fluid (SRF), and subfoveal choroidal thickness (SCT) were observed at baseline and after treated at 1, 2, 3, 6 and 12 months with EDI-OCT, Best-corrected visual acuity ( BCVA) was also studied at the same time. Results: After 1, 2, 3 and 6 months of 1/3-dose verteporfin PDT treatment, the BCVA improved significantly (P 0.05). The height of SRF changed significantly. There was no retinal pigment epithelium atrophy and choroidal neovascularization (CNV) in all cases after more than 12 months follow-up. Conclusion: Treatment of 1/3 dose verteporfin PDT could safely and effectively reduce expansion of choroidal vessel and choroidal choriocapillary, promoting absorbance of subretinal fluid for subacute CSC. 1/3-dose verteporfin PDT may be an alternative method to treat the subacute CSC.展开更多
Background:To find the changes of macular perimetry(MP) and the correlations between MP and best correct visual acuity(BCVA) in different phases of the acute central serous chorioretinopathy(CSC).Methods:Twenty-one ey...Background:To find the changes of macular perimetry(MP) and the correlations between MP and best correct visual acuity(BCVA) in different phases of the acute central serous chorioretinopathy(CSC).Methods:Twenty-one eyes with acute CSC and their fellow eyes were analysed retrospectively.MP at 2°,4°and BCVA in the active and resolved phase were collected and analyzed.The differences of these parameters in CSC eyes and fellow eyes were analyzed.Spearman correlation was used for analysis of correlation between MP and BCVA.Results:From 29 eyes with CSC analysed 27 eyes(93.10%) recovered to the previous VA.Compared with the active phase,MP at 2°,4° and BCVA were significantly improved in the resolved phase(P=0.000,0.000,0.000,respectively).MP at 2°,4° and BCVA of CSC eyes were significantly poor compared with the fellow eyes in the active phase(P=0.000,0.000,0.000,respectively).In the resolved phase there was no significant difference between the CSC eyes and fellow eyes(P=0.339,0.141,0.161,respectively).BCVA was shown to significantly correlate with MP at 2° in the active phase(ρ=-0.630,P<0.001).Conclusions:The acute CSC often had a good prognosis both in BCVA and MP.MP can provide an additional objective parameter to evaluate the retinal function changes at macula of acute CSC.展开更多
文摘Purpose: To study the safety and efficacy of 1/3-dose verteporfin photodynamic therapy (PDT) for subacute central serous chorioretinopathy (CSC). Methods: In this case series, 59 eyes (59 patients) diagnosed with subacute CSC in Shenyang the 4th hospital from January 2014 to December 2015 were treated with 1/3-dose verteporfin PDT and followed up for at least 1 year. The symptoms and the diagnosed history were more than 3 months but shorter than 6 months. The central foveal thickness (CFT), neuroretinal thickness (NRT), height of subfoveal retinal fluid (SRF), and subfoveal choroidal thickness (SCT) were observed at baseline and after treated at 1, 2, 3, 6 and 12 months with EDI-OCT, Best-corrected visual acuity ( BCVA) was also studied at the same time. Results: After 1, 2, 3 and 6 months of 1/3-dose verteporfin PDT treatment, the BCVA improved significantly (P 0.05). The height of SRF changed significantly. There was no retinal pigment epithelium atrophy and choroidal neovascularization (CNV) in all cases after more than 12 months follow-up. Conclusion: Treatment of 1/3 dose verteporfin PDT could safely and effectively reduce expansion of choroidal vessel and choroidal choriocapillary, promoting absorbance of subretinal fluid for subacute CSC. 1/3-dose verteporfin PDT may be an alternative method to treat the subacute CSC.
文摘Background:To find the changes of macular perimetry(MP) and the correlations between MP and best correct visual acuity(BCVA) in different phases of the acute central serous chorioretinopathy(CSC).Methods:Twenty-one eyes with acute CSC and their fellow eyes were analysed retrospectively.MP at 2°,4°and BCVA in the active and resolved phase were collected and analyzed.The differences of these parameters in CSC eyes and fellow eyes were analyzed.Spearman correlation was used for analysis of correlation between MP and BCVA.Results:From 29 eyes with CSC analysed 27 eyes(93.10%) recovered to the previous VA.Compared with the active phase,MP at 2°,4° and BCVA were significantly improved in the resolved phase(P=0.000,0.000,0.000,respectively).MP at 2°,4° and BCVA of CSC eyes were significantly poor compared with the fellow eyes in the active phase(P=0.000,0.000,0.000,respectively).In the resolved phase there was no significant difference between the CSC eyes and fellow eyes(P=0.339,0.141,0.161,respectively).BCVA was shown to significantly correlate with MP at 2° in the active phase(ρ=-0.630,P<0.001).Conclusions:The acute CSC often had a good prognosis both in BCVA and MP.MP can provide an additional objective parameter to evaluate the retinal function changes at macula of acute CSC.
文摘目的观察中药联合半剂量维替泊芬光动力疗法(photodynamic therapy,PDT)治疗慢性中心性浆液性脉络膜视网膜病变(central serous chororetinopathy,CSC)的效果。方法对27例36眼慢性CSC患者,行半剂量维替泊芬PDT治疗,术后根据中医辨证施治原则配合中药汤剂治疗,随访6~12个月,以最佳矫正视力(best corrected visual acuity,BCVA)、视网膜下液隆起最高点高度(the height of highest point of subretinal fluid,HPSF)作为疗效指标,观察该法有效率及复发率。结果治疗后3个月、6个月及末次随访时BCVA提高,与治疗前相比差异有统计学意义。治疗后1个月内视网膜下液吸收明显。末次随访时,显效22眼(61.11%),有效11眼(30.56%),总有效率91.76%。随访过程中1眼复发,经再次中药联合半量PDT治疗后好转。随访期间36眼未见不良反应。结论中药联合半剂量维替泊芬光动力疗法治疗慢性CSC安全有效,有效降低复发率。
